EIZO (6737) Q3 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2025 earnings summary
18 Mar, 2026Executive summary
Net sales for 24Q3 were JPY58.1B, nearly flat year-over-year at 99.9% of the previous year.
Operating income declined to JPY2.1B, down 15.3% year-over-year, mainly due to higher SG&A expenses.
Net income dropped to JPY1.9B, a 46.7% decrease year-over-year, impacted by foreign exchange losses and absence of prior year investment gains.
Comprehensive income fell sharply to JPY1.37B from JPY9.3B in the prior year period.
Financial highlights
Gross profit increased to JPY19.2B, with gross margin rising to 33.0% from 32.2% year-over-year.
SG&A expenses rose 5.4% year-over-year to JPY17.0B, driven by wage increases and R&D investment.
Ordinary income fell to JPY3.0B, down 34% year-over-year.
Earnings per share for the nine months was JPY48.44, down from JPY90.90 year-over-year (adjusted for share split).
Equity ratio remained strong at 79.0% as of December 31, 2024.
Foreign exchange loss of JPY0.3B compared to a gain of JPY0.6B in the prior year.
Outlook and guidance
FY24 net sales forecast at JPY81.0B, up 0.7% from FY23.
Operating income projected at JPY4.0B, up 2.3% year-over-year.
Net income guidance at JPY3.4B, a 37.7% decrease from FY23.
Earnings per share for the full year is forecast at JPY82.61 (adjusted for share split).
No revision to FY24 guidance as of October 31, 2024.
Latest events from EIZO
- Profits fell on weak demand, but full-year growth and a share split are forecast.6737
Q1 202518 Mar 2026 - Profits and comprehensive income fell sharply, with a modest sales outlook and share split enacted.6737
Q2 202518 Mar 2026 - Flat sales and lower profit, but FY2026 outlook targets growth and higher dividends.6737
Q4 202518 Mar 2026 - Sales and profits fell on European weakness, but margin and new products support future outlook.6737
Q1 202618 Mar 2026 - Healthcare and Amusement drove 2.9% sales growth, but profits were pressured by higher SG&A.6737
Q2 202618 Mar 2026 - Net sales rose, but profit outlook was cut due to higher costs and weak European demand.6737
Q3 202618 Mar 2026